Table II.

Characteristics of patients enrolled.

Parameters	Data N=50
Age (years), mean±SD	64.4±7.2
PSA level (ng/ml), median (Q1; Q3)	11.9 (7.6; 20.7)
Gleason score biopsy, median (Q1; Q3)	7.0 (6.0; 7.0)
Gleason score prostatectomy, median (Q1; Q3)	7.0 (7.0; 7.0)
mp-MRI with ERC, n (%)	23 (46.0%)
Positive TRUS-guided biopsy before mp-MRI, n (%)	36 (72.0%)
Time prostate biopsy-to-MRI (weeks), median (Q1; Q3)	6.0 (5.0; 8.5)
Time MRI-to-prostatectomy (weeks), median (Q1; Q3)	4.5 (2.0; 8.5)
Hemorrhagic findings in mp-MRI performed after biopsy, n (%)	23 (63.9%)

SD = standard deviation; Q1 = quartile 1; Q3 = quartile 3; n (%) = number (percentage) of patients; PSA = prostate-specific antigen; ERC = endorectal coil; mp-MRI = multiparametric MRI.